Resistance testing. NLM AIDSLINE Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Resistance testing.

Posit Aware. 1997 Jul/Aug;8(4):35-7. Unique Identifier : AIDSLINE MED/97702775
Munk B; Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD; 20849-6003. 800-458-5231 ext. 5714. A fee will apply.

Abstract: Clinical resistance, phenotypic resistance, genotypic resistance, and drug resistance are a few of the terms used to define resistance. Drug resistance refers to HIV's ability to live and multiply even when it is exposed to a lethal dose of antiviral drugs. Clinical resistance occurs when a patient's HIV disease gets worse despite using medications that are usually effective. Phenotypic resistance refers to HIV that can live in a test tube containing what should be a lethal dose of an antiviral drug. A virus has genotypic resistance if it contains mutations. Researchers have a clearer picture of resistance to protease inhibitors and non-nucleoside reverse transcriptase inhibitors. These drugs work by physically locking onto the enzyme and blocking the working part of the enzyme molecule. Although tests for genotypic and phenotypic resistance are becoming commercially available, it is not yet clear how accurate or useful these tests will be in terms of changing antiviral drug regimens. Resistance questions will be addressed in a research study being conducted by the Community Programs for Clinical Research on AIDS (CPCRA) of the National Institutes of Health (NIH). The Genotypic Antiretroviral Resistance Testing (GART) protocol will determine whether there is any difference in the viral load between patients who are using current antiviral therapy management to those who have the results of genotypic testing available to their physicians.
Keywords: *Diagnostic Services *Drug Resistance, Microbial *HIV Infections/DRUG THERAPY *HIV-1/DRUG EFFECTS *MutationKWDdiagnosticservicesKWDdrugresistance,microbialKWDhivinfections/drugtherapyKWDhiv-1/drugeffectsKWDmutation
971230
M97C1551

Copyright © 1997 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .